合理设计
连接器
结合
癌症研究
计算生物学
计算机科学
模块化设计
化学
相容性(地球化学)
药品
抗癌药
药理学
药物输送
纳米技术
生物信息学
硼替佐米
药物发现
作者
Yu Lian Guo,Yi Song,Hanlin Wang,Lu Yang,Jingyu Zhang,Zheyuan Shen,Weijuan Kan,Yuxian Wang,Haiting Duan,Shuangshuang Geng,Bo Wang,Shaoting Li,Bizhi Li,Xi Chen,Shanshan Pei,Luo Fang,Jia Li,Yubo Zhou,Jinxin Che,Xiaowu Dong
标识
DOI:10.1016/j.apsb.2025.09.009
摘要
Degrader–antibody conjugates (DACs) represent a promising drug modality for targeting hematological malignancy, but still lack rational design frameworks. Here, we show the strategies of reasonable antibody-degrader compatibility and degradation tail-derived conjugatability through a systematic exploration. Inspired by the success of IKZF1/3 degraders, we sought to explore the potential of cereblon E3 ligase modulators (CELMoDs) in constructing novel conjugates. By combining a modular library with neo-substrate screening and further conjugatable derivation, I034 was identified, a potent CELMoD payload with picomolar degradation activity and antiproliferative effects. Through linker chemistry, I034 -based DACs were constructed and demonstrated superior efficacy and safety compared to auristatin-based conjugates both in vitro and in vivo , with the CD38-targeting Dara-VA- I034 achieving complete tumor eradication at low doses. Mechanistic insights revealed distinct positive feedback regulation of CD38 conjugates, highlighting the need for compatibility between payloads and antigens. These results demonstrate that the approach could provide a framework for discovering CELMoD payloads and advancing DACs for treating multiple myeloma and other malignancies. Rationally engineered CELMoD–antibody conjugates (Dara-VA-I034) enable complete tumor eradication via CD38-targeted degradation with a unique positive-feedback loop, outperforming auristatin-based ADCs in efficacy and safety.
科研通智能强力驱动
Strongly Powered by AbleSci AI